In the realm of oncogene target validation and dynamics-structure-based targeted drug design, our research focuses on H3K36 methyltransferases (KMTs) and transcription factors belonging to the BTB family. Through our investigations on KMTs, we have made significant contributions in the field of lung cancer by identifying novel oncogenes, their recurrent missense mutations, and elucidating the molecular bases of their hyperactivity that drive cancerous transformations.